These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Role of antiarrhythmics in the post-infarction period].
    Author: Dinanian S.
    Journal: Arch Mal Coeur Vaiss; 2000 Apr; 93(3 Spec No):65-9. PubMed ID: 10816803.
    Abstract:
    In the thrombolytic era, the mortality of myocardial infarction has been considerably reduced. The prognosis has also improved due to early treatment and the correction of residual ischaemia. Betablockers are valuable antiarrhythmic agents, both in the acute and chronic phases of infarction. Irrespective of the size of the infarct scar, a better prognosis is observed in patients taking betablockers. Class I antiarrhythmics, though, should be proscribed after the results of the CAST studies: these antiarrhythmics are effective on ventricular arrhythmias but do not improve the prognosis because of their proarrhythmic effects aggravated by ischaemia or left ventricular dysfunction. Of the Class III antiarrhythmics, amiodarone has been shown to reduce the incidence of sudden death in the post-infarction period in patients with ventricular hyperexcitability or severe left ventricular dysfunction. At present, classical antiarrhythmic therapy is opposed to the implantation of an automatic defibrillator in cases of serious arrhythmias after myocardial infarction.
    [Abstract] [Full Text] [Related] [New Search]